Sotac Pharmaceuticals Share Price Today | Stock Price & Sotac Pharmaceuticals Share Screener
Track the current Sotac Pharmaceuticals share price and stock price live with TickJournal's free stock screener. Check Sotac Pharmaceuticals 52-week for the annual price range and momentum. Use the Sotac Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sotac Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹28 and net income of ₹1, with EBITDA of ₹3, an operating margin of 8.0% and a profit margin of 3.6%.
Sotac Pharmaceuticals Share Price Chart
Track the current stock price of Sotac Pharmaceuticals with an interactive chart. Analyse SOTAC share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sotac Pharmaceuticals stock quote in one place.
Sotac Pharmaceuticals Company Profile - Fundamental Screener
Screen Sotac Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SOTAC shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0O2D01012.
Company Details
Classification
Identifiers and Leadership
Sotac Pharmaceuticals Balance Sheet Screener
Screen SOTAC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹134, up from ₹124 in 2025.
Latest statistics put total assets at ₹134 and shareholder funds at ₹59, with a leverage ratio of 0.70.
| Item | 2026 | 2025 | 2024 | 2023 | 2021 | 2020 |
|---|---|---|---|---|---|---|
Assets |
||||||
| Total Assets | 134 | 124 | 105 | 74 | 35 | 30 |
| Current Assets | 78 | 70 | 61 | 47 | 17 | 14 |
| Fixed Assets | 50 | 49 | 36 | 26 | 17 | 16 |
Liabilities |
||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 11 | 14 | 12 | 8 | 9 | 6 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||
| Total Equity | 59 | 58 | 49 | 20 | 3 | 5 |
| Share Capital | 11 | 11 | 11 | 8 | 2 | 2 |
| Reserves & Surplus | 48 | 42 | 34 | 2 | 0 | 1 |
Sotac Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Sotac Pharmaceuticals income statement and profit fundamentals. Analyze SOTAC quarterly results. Sotac Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2024-Sept, revenue was ₹28 and net profit was ₹1, equal to earnings per unit of ₹0.42, at an operating margin of 8%.
In that period expenses were ₹25, interest cost ₹1 and tax ₹1. The next period listed, 2024-Jun, shows revenue of ₹26 and net profit of ₹2.
| Item | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 28 | 26 | 27 | 26 | 27 | 25 | 18 | 20 | 41 |
| Expenses | 25 | 23 | 25 | 23 | 25 | 23 | 16 | 18 | 36 |
Operating Costs and Margins | |||||||||
| EBITDA | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 2 | 4 |
| Operating Profit % | 8.00% | 9.00% | 4.00% | 10.00% | 8.00% | 9.00% | 13.00% | 9.00% | 9.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
Profit and Earnings | |||||||||
| Profit Before Tax | 1 | 1 | 0 | 2 | 1 | 2 | 1 | 1 | 2 |
| Tax | 1 | 0 | -1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Net Profit | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | 0.42 | 1.32 | 1.49 | 0.82 | 0.58 | 1.01 | 1.58 | 0.29 | 4.41 |
Sotac Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SOTAC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹4, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹14 and financing activities provided ₹16.
| Item | 2025-March | 2024-March | 2023-March | 2021-March | 2020-March |
|---|---|---|---|---|---|
Cash from Operations and Investing | |||||
| Operating Activities | -4 | -16 | 8 | 0 | 0 |
| Investing Activities | -14 | -20 | -12 | -3 | -12 |
Financing and Net Cash | |||||
| Financing Activities | 16 | 30 | 13 | 3 | 11 |
| Net Cash Flow | -2 | -6 | 10 | 0 | 0 |
Sotac Pharmaceuticals Shareholding Pattern Screener
See Sotac Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Sotac Pharmaceuticals promoter holding and ownership changes for SOTAC on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 72.85%, foreign institutions 16.79%, domestic institutions 0.00% and the public 6.52%, spread across 221 shareholders.
The shareholder count was 221 in 2026-Mar, compared with 243 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Sept | 2024-Mar | 2024-Sept | 2023-Apr | 2023-Sept |
|---|---|---|---|---|---|---|---|
Promoter Holding | |||||||
| Promoter Holding | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% |
Institutional Investors | |||||||
| FII Holding | 16.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | |||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.52% | 4.70% | 5.13% | 5.82% | 6.01% | 8.19% | 5.32% |
| Other Holding | 3.84% | 22.45% | 22.02% | 21.33% | 21.14% | 18.96% | 21.83% |
| Shareholder Count | 221 | 243 | 240 | 245 | 251 | 784 | 255 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sotac Pharmaceuticals. Sotac Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
Sotac Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Sotac Pharmaceuticals stock. Check SOTAC index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Sotac Pharmaceuticals Market Events Screener - Corporate Actions
Get Sotac Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sotac Pharmaceuticals stock events that may affect SOTAC share price, along with derivatives, futures and options activity and sector gainers.
7 corporate actions are listed, the most recent entry being Dividend dated September 23, 2026, with a record date of September 23, 2026.
It is followed by Quarterly Result Announcement dated May 26, 2026 and Quarterly Result Announcement dated November 12, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-23 | 2026-09-23 | Dividend | ₹ 0.20 /share | -18.87% |
| 2026-05-26 | 2026-05-26 | Quarterly Result Announcement | NA | -0.27% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -0.65% |
| 2025-09-19 | 2025-09-19 | Dividend | ₹ 0.10 /share | 1.16% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -0.21% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -4.97% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -12.52% |
Sotac Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen SOTAC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,053 | 36.83 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 249,129 | 86.00 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 183,014 | 86.72 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 116,219 | 25.96 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 110,006 | 33.29 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 107,057 | 98.39 | 6,868 | 22.01% | 890 | 58.00 |
| Dr Reddys Laboratories | 103,634 | 32.77 | 35,059 | 3.90% | 4,158 | 69.59 |
| Mankind Pharma | 103,493 | 50.84 | 14,636 | 14.85% | 1,938 | 64.24 |
| Aurobindo Pharma | 96,675 | 26.41 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,882 | 16.97 | 29,039 | 26.75% | 5,356 | 34.02 |
Sotac Pharmaceuticals Company Announcements - News & Reports Screener
Screen SOTAC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
Frequently Asked Questions
How is the company valued right now?
The P/E ratio is 17.25 and the P/B ratio is 1.69, with earnings per unit of ₹5.22. Market capitalisation stands at ₹99.51 Cr and the dividend yield is 0.22%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 6, 2026. This page covers 6 balance sheet periods, 9 income statement periods, 5 cash flow years and 7 shareholding periods. Information is provided for research and is not investment advice.